Avacta Group Plc’s (AIM: AVCT) issued ordinary share count has expanded from 369.4 million at the end of 2024 to an estimated 471.7 million based on its latest capital filings, an increase of approximately 102.3 million shares, or 27.7%, in about 19 months. The AIM-listed oncology developer, which trades under the ticker AIM: AVCT, has repeatedly used equity to fund research, extend its operating runway and reduce exposure to a convertible bond originally issued to support its former diagnostics strategy.
The ownership effect is smaller than the share-count increase but still material. A shareholder who held the same number of shares throughout the period and did not participate in new issues would retain approximately 78.3% of the proportional ownership held at December 31, 2024. That equates to ownership dilution of about 21.7%, before considering any future exercise of outstanding options or warrants.
The funding cannot be judged on dilution alone. Avacta raised £41.5 million in gross equity through five placings and related subscriptions between July 2025 and June 2026. It also moved AVA6103 into Phase 1, advanced AVA6000 and increased research spending while reducing selling, general and administrative expenses.
Three raises representing £15.5 million of gross proceeds were expressly linked to convertible-bond payments. That is 37.3% of the funding cycle, although it is not equivalent to £15.5 million of principal reduction because issue costs, interest and fees also consumed cash.
The resulting trade-off is now clear. Avacta has exchanged immediate dilution for clinical time and a lower bond balance, but its stated runway reaches only into early in the first quarter of 2027. The late-2026 AVA6103 data and maturing AVA6000 evidence therefore need to improve partnering or financing options before the company again approaches a capital constraint.
How much has Avacta diluted existing shareholders since 2024?
Avacta reported 369,406,389 ordinary shares at December 31, 2024 and 440,415,495 at December 31, 2025. The first year therefore added 71,009,106 shares, increasing the share count by 19.2%.
The 2025 accounts reconcile that increase in full. Cash placings added 42,730,139 shares, or 60.2% of the annual increase. Bond settlements added 16,047,934 shares, or 22.6%, while option exercises contributed 12,231,033 shares, or 17.2%.
In 2026, the March financing added 15,873,016 shares at 63 pence, a May bond conversion added 1,604,063 shares, and the June financing issued 12,857,143 shares at 70 pence. The June announcement put issued capital at 471,330,508 shares. Later Companies House statements imply 471,705,508 ordinary shares after allowing for unchanged deferred-share capital. The remaining 955,791-share increase is classified as other allotments because the available records do not support a more specific attribution.
Using the latest filing-implied count, Avacta has added 102,299,119 ordinary shares since the end of 2024. Share-count growth is 27.7%, while ownership dilution for a passive holder is 21.7%. The distinction matters because dilution is calculated by comparing the original holding with the enlarged denominator, not by simply repeating the percentage increase in shares.
Where did Avacta’s £41.5m of equity funding actually go?
The £41.5 million gross total comprises £3.25 million raised in July 2025, £3.25 million in August 2025, £16 million in October 2025, £10 million in March 2026 and approximately £9 million in June 2026.
The July 2025 placing funded a cash bond instalment comprising £2.55 million of principal and approximately £414,000 of interest. The August placing generated about £3.1 million net for the October repayment. The June 2026 raise was intended for accelerated deferred repayments and potentially an additional quarterly payment.
Those bond-linked raises had gross proceeds of £15.5 million. The more defensible conclusion is that 37.3% of the gross equity cycle was associated with servicing or reducing the bond, not that the full amount reduced principal.
The other £26 million came from the October 2025 and March 2026 raises. Avacta presented these primarily as working capital for research, including progressing AVA6103 to initial data and extending the stated runway into early in the first quarter of 2027.
Gross fundraising therefore cannot be added mechanically to operating runway. Capital reserved for bond obligations can improve the balance sheet, but it is not simultaneously available for clinical spending.
How much convertible-bond exposure remains after July’s cash payment?
Avacta’s convertible bond was issued in October 2022 with £55 million of face value at 95% of par. It carries a 6.5% contractual cash coupon and mandatory quarterly amortisation. The accounts also report a 49.99% effective interest rate for the debt liability, an accounting measure reflecting the instrument’s structure and embedded derivative, not a 49.99% cash coupon.
Principal outstanding was £20.4 million at December 31, 2025. The May conversion reduced it by £1.2 million to £19.2 million. Avacta then paid £3.67 million in cash in July, of which £2.4 million was principal and the remainder represented associated interest and deferral fees. Principal consequently fell to £16.8 million, a reduction of £3.6 million, or 17.6%, from year-end.
At a 67 pence share price and the latest filing-implied count, Avacta’s equity value is approximately £316 million, placing remaining principal at about 5.3% of equity value. The bond balance is also slightly larger than the £16.4 million cash position reported at April 30, although the June bond financing occurred afterward.
Does £16.4m of April cash support the early-2027 runway?
Avacta’s 2025 cash-flow statement separates the business that it retained from the diagnostics operations it sold. Net cash used in continuing operating activities was £23.876 million, while discontinued operations used another £2.906 million. Using the £26.782 million group total would overstate the recurring burn of the post-disposal therapeutics business.
The continuing-operation figure equates to average net operating cash use of approximately £1.99 million a month. Dividing the April 30 cash balance of £16.4 million by that rate gives about 8.2 months of coverage, broadly reaching early January 2027. Using the £24.927 million continuing operating outflow before interest received, lease interest and tax receipts gives approximately 7.9 months. Both approaches are broadly consistent with management’s guidance of runway into early in the first quarter of 2027.
This is a straight-line stress test, not a company forecast. Clinical expenditure is uneven, and tax receipts and working-capital movements do not arrive monthly. The calculation also excludes the June £9 million gross raise from unrestricted cash because the proceeds were designated for bond payments.
Avacta’s runway claim is therefore broadly consistent with audited continuing-operation cash use, but the buffer after the expected late-2026 AVA6103 readout appears limited. Delayed data or faster trial spending could bring the next financing decision closer.
Has Avacta shifted spending from overheads to research?
Research costs increased from £14.266 million in 2024 to £18.761 million in 2025, a rise of 31.5%. Selling, general and administrative expenses moved in the opposite direction, falling from £12.046 million to £9.239 million, or by 23.3%.
Research represented 67.0% of the combined research and selling, general and administrative cost base in 2025, up from 54.2% in 2024. This shows that spending became more concentrated on development activity, although it does not prove that every additional pound was productive.
The continuing business generated only £113,000 of revenue in 2025, unchanged from the previous year, so it remains dependent on external capital. Clinical progress is therefore the principal test of whether the increased research allocation can create value greater than the dilution used to finance it.
Avacta reported four confirmed partial responses and eight confirmed minor responses among 32 patients in its pivotal-study-aligned salivary gland cancer population for AVA6000, with median progression-free survival still immature. The United States Food and Drug Administration also agreed on a potential route involving one pivotal study with progression-free survival as the sole primary endpoint. Avacta has said further development of AVA6000 would require partner support, making a partnership a financing event as well as a clinical endorsement.
How does Avacta’s valuation compare with its recent placing prices?
Avacta shares closed at 67 pence on August 7, 2026, down 0.7% in the session. The price was approximately 0.8% above the July 31 close over five trading days, while the standard trailing one-month return was negative 5.0%. The 52-week trading range was 41.33 pence to 92 pence.
The closing price was 6.3% above the 63 pence March issue price but 4.3% below the 70 pence June issue price. At 67 pence, the latest filing-implied count produces an equity value of about £316 million, making the £41.5 million funding cycle equivalent to 13.1% of current equity value.
This does not establish whether Avacta is cheap or expensive. The 70 pence marker matters because the June raise was completed without a discount to the previous closing mid-market price and was intended to replace potentially lower-priced share settlements under the bond.
Avacta’s late-2026 data now carries a larger per-share burden
Avacta has aligned more spending with its oncology strategy and reduced some convertible-bond risk, but paid for that transition with a substantially larger share base. The 27.7% increase is not automatically value-destructive if AVA6000 and AVA6103 create more value than the dilution absorbs, but it raises the equity value required to deliver the same result per share.
Research intensity increased while selling, general and administrative expenses declined, and cash payments reduced the prospect of price-linked bond settlements. Against that, £16.8 million of principal and an operating runway extending only into early 2027 leave limited room for clinical delays or a prolonged partnering process.
An updated bridge showing unrestricted cash, amounts reserved for bond payments, current principal and revised runway would materially change the analysis. A funded AVA6000 partnership or compelling AVA6103 data could reduce dependence on another broad equity raise. Delays, higher trial costs or further bond acceleration would do the opposite.
Avacta has bought time and reduced one source of financing uncertainty, but it has not eliminated the need for external capital. The next test is whether the late-2026 evidence can convert that purchased time into funding leverage before the enlarged share base has to absorb another material financing round.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
